Trial site
Synexus Polska Sp. z o.o.
Lodz, 90-127, PolandEU-13 widening countryNot linked to an institution yet
- 14running trials
- 8closed trials
The trials here
What the 22 trials at this site are about, from their registry records.
- Phase
- Phase 316 trials
- Phase 25 trials
- Phase 2/31 trial
- Status
- Active, not recruiting8 trials
- Completed7 trials
- Recruiting6 trials
- Terminated1 trial
- Lead sponsor
- Akero Therapeutics Inc.2 trials
- Ascletis Pharma (China) Co. Ltd.2 trials
- Novo Nordisk A/S2 trials
- Pfizer2 trials
- Sanofi2 trials
- and 12 more
Running trials
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Recruiting
Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Weight-Related Comorbidities
2026-526172-23-00· Phase 3· Ascletis Pharma (China) Co. Ltd.· Source
Recruiting
Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus
2026-526336-39-00· Phase 3· Ascletis Pharma (China) Co. Ltd.· Source
Active, not recruiting
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients with Type 2 Diabetes Mellitus
2025-524514-28-00· Phase 2· Corxel Pharmaceuticals Inc.· Source
Active, not recruiting
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
NCT07400653· Phase 3· Pfizer· Source
Active, not recruiting
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
NCT07311850· Phase 3· Pfizer· Source
Recruiting
Clinical trial to investigate the efficacy and tolerability of Lipovir® Gel (Acyclovir 5%) compared to Zovirax® Cream (Acyclovir 5%) and placebo on patients with recurrent herpes labialis
2023-510338-10-00· Phase 3· Laboratorios Ojer Pharma S.L.· Source
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH)
2024-512895-36-00· Phase 3· Akero Therapeutics Inc.· Source
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
2023-505141-48-00· Phase 3· Akero Therapeutics Inc.· Source
Active, not recruiting
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741· Phase 2· Nektar Therapeutics· Source
Terminated
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06058156· Phase 2· Sanofi· Source
Active, not recruiting
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
NCT05492578· Phase 2/3· Sanofi· Source
Active, not recruiting
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728· Phase 3· Inventiva Pharma· Source
Active, not recruiting
A clinical trial to evaluate the safety and effectiveness of MGL-3196 (resmetirom) in patients with Non-Alcoholic Steatohepatitis (NASH) and reduce progression of liver damage and resolve NASH
2024-510626-89-00· Phase 3· Madrigal Pharmaceuticals Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error